TY - JOUR
T1 - SARS-CoV-2 infection in cystic fibrosis
T2 - A multicentre prospective study with a control group, Italy, February-July 2020
AU - Colombo, Carla
AU - Alicandro, Gianfranco
AU - Dacco, Valeria
AU - Gagliano, Vanessa
AU - Morlacchi, Letizia Corinna
AU - Casciaro, Rosaria
AU - Pisi, Giovanna
AU - Francalanci, Michela
AU - Badolato, Raffaele
AU - Bignamini, Elisabetta
AU - Messore, Barbara
AU - Lucanto, Maria Cristina
AU - Leonetti, Giuseppina
AU - Maschio, Massimo
AU - Cipolli, Marco
N1 - Publisher Copyright:
© 2021 Colombo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2021/5
Y1 - 2021/5
N2 - Objective To describe the symptoms and clinical course of SARS-CoV-2 infection in patients with cystic fibrosis (CF). Methods We carried out a prospective multicentre cohort study based on 32 CF centres and 6597 patients. Centres were contacted to collect baseline and follow-up data of patients who reported symptoms suggestive of COVID-19 or who had contact with a positive/suspected case between the end of February and July 2020. Symptoms and clinical course of the infection were compared between patients who tested positive by molecular testing (cases) and those who tested negative (controls). Results Thirty patients were reported from the centres, 16 of them tested positive and 14 tested negative. No differences in symptoms and outcome of the disease were observed between groups. Fever, cough, asthenia and dyspnea were the most frequently reported symptoms. Eight cases (50%) were hospitalized but none required ICU admission. Two adults with a history of lung transplant required non-invasive ventilation, none required ICU admission and all patients fully recovered without short-term sequelae. Conclusions The course of SARS-CoV-2 in our patients was relatively favorable. However, COVID-19 should not be considered a mild disease in CF patients, particularly for those with severely impaired respiratory function and organ transplant.
AB - Objective To describe the symptoms and clinical course of SARS-CoV-2 infection in patients with cystic fibrosis (CF). Methods We carried out a prospective multicentre cohort study based on 32 CF centres and 6597 patients. Centres were contacted to collect baseline and follow-up data of patients who reported symptoms suggestive of COVID-19 or who had contact with a positive/suspected case between the end of February and July 2020. Symptoms and clinical course of the infection were compared between patients who tested positive by molecular testing (cases) and those who tested negative (controls). Results Thirty patients were reported from the centres, 16 of them tested positive and 14 tested negative. No differences in symptoms and outcome of the disease were observed between groups. Fever, cough, asthenia and dyspnea were the most frequently reported symptoms. Eight cases (50%) were hospitalized but none required ICU admission. Two adults with a history of lung transplant required non-invasive ventilation, none required ICU admission and all patients fully recovered without short-term sequelae. Conclusions The course of SARS-CoV-2 in our patients was relatively favorable. However, COVID-19 should not be considered a mild disease in CF patients, particularly for those with severely impaired respiratory function and organ transplant.
UR - http://www.scopus.com/inward/record.url?scp=85105814100&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105814100&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0251527
DO - 10.1371/journal.pone.0251527
M3 - Review article
C2 - 33984027
AN - SCOPUS:85105814100
VL - 16
JO - PLoS One
JF - PLoS One
SN - 1932-6203
IS - 5 May
M1 - e0251527
ER -